rimo-301
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 10, 2018 (NCT03444714)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05838729 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2023 | Coordination Pharmaceuticals, Inc., University of Illinois at Chicago |
| NCT03444714 | Phase 1 | Apr 10, 2018 | Rimo Therapeutics Inc., University of Chicago |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Coordination Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Rimo Therapeutics Inc. | For profit | 1 | 1 | 1 | 2018 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Illinois at Chicago | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1